A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors
In the last 3 years, a novel class of targeted therapy has been approved for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. There are currently three approved agents, which are oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitors...
Main Authors: | Mariane Teodoro Fernandes, Jacob J Adashek, Carmelia Maria Noia Barreto, Ana Cláudia Barbin Spinosa, Barbara de Souza Gutierres, Gilberto Lopes, Auro del Giglio, Pedro Nazareth Aguiar Jr |
---|---|
Format: | Article |
Language: | English |
Published: |
BioExcel Publishing Ltd
2018-11-01
|
Series: | Drugs in Context |
Subjects: | |
Online Access: | https://www.drugsincontext.com/a-paradigm-shift-for-the-treatment-of-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-hr-her2-advanced-breast-cancer-a-review-of-cdk-inhibitors |
Similar Items
-
Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
by: Navid Sobhani, et al.
Published: (2019-04-01) -
Mouse Model of Congenital Heart Defects, Dysmorphic Facial Features and Intellectual Developmental Disorders as a Result of Non-functional CDK13
by: Monika Nováková, et al.
Published: (2019-08-01) -
Docking to a Basic Helix Promotes Specific Phosphorylation by G1-Cdk1
by: Ilona Faustova, et al.
Published: (2021-09-01) -
Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
by: Gaia Giannone, et al.
Published: (2019-05-01) -
Immunological characterization and histone kinase activity of cyclin B1 and Cdk1 at G1 and G2/M phase of the cell division cycle in one-cell mouse embryos
by: Dann, Jeremiah J.
Published: (2011)